Compare RBB & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBB | GLSI |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.4M | 372.0M |
| IPO Year | 2017 | 2020 |
| Metric | RBB | GLSI |
|---|---|---|
| Price | $21.91 | $23.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $22.00 | ★ $50.00 |
| AVG Volume (30 Days) | 54.4K | ★ 244.5K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $5,293,000.00 | N/A |
| Revenue This Year | $15.23 | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | $17.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.40 | $7.78 |
| 52 Week High | $22.69 | $34.10 |
| Indicator | RBB | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 57.23 | 44.73 |
| Support Level | $20.04 | $9.47 |
| Resistance Level | $22.54 | $32.61 |
| Average True Range (ATR) | 0.49 | 2.25 |
| MACD | 0.00 | -0.95 |
| Stochastic Oscillator | 62.32 | 18.80 |
RBB Bancorp operates as a bank holding company. It provides various banking products and services such as checking, savings, money market accounts, and certificates of deposits. Its Specific services include remote deposit, E-banking, mobile banking, commercial and investor real estate loans, business loans and lines of credit, Small Business Administration (SBA) 7A and 504 loans, mortgage loans, trade finance, and a full range of depository accounts. It generates its revenue from interest received on loans and leases and, to a lesser extent, from interest received on investment securities and derives income from noninterest sources, such as fees received in connection with various lending and deposit services, loan servicing, gain on sales of loans, and wealth management services.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.